

Table S4 Grading of recommendations assessment, development and evaluation (GRADE) evidence table for conjunctivitis in patients receiving dupilumab versus placebo.

| Certainty assessment | | | | | | | Event rate | | Effect | | Certainty | Importance |
|---|--------------|--------------|----------------------|--------------|----------------------|----------------------|------------------|-----------------|------------------------|---|--------------|------------|
| Number of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Dupilumab | Placebo | Relative (95% CI) | Absolute (95% CI) | | |
| Conjunctivitis in patients receiving dupilumab versus placebo | | | | | | | | | | | | |
| 23 | RCTs | not serious | serious ^a | not serious | serious ^b | none | 366/6040 (6.1%) | 101/3113 (3.2%) | RR 1.89 (1.34 to 2.67) | 29 more per 1,000 (from 11 more to 54 more) | ⊕⊕○○ Low | Critical |
| Conjunctivitis in patients with AD receiving dupilumab versus placebo | | | | | | | | | | | | |
| 14 | RCTs | not serious | not serious | not serious | not serious | none | 319/3096 (10.3%) | 70/1627 (4.3%) | RR 2.43 (1.89 to 3.12) | 63 more per 1,000 (from 38 more to 91 more) | ⊕⊕⊕⊕ High | Critical |
| Conjunctivitis in patients with non-AD indications receiving dupilumab versus placebo | | | | | | | | | | | | |
| 9 | RCTs | not serious | not serious | not serious | not serious | none | 47/2944 (1.6%) | 31/1486 (2.1%) | RR 0.71 (0.44 to 1.13) | 6 fewer per 1,000 (from 12 fewer to 3 more) | ⊕⊕⊕⊕ High | Critical |

Abbreviations: CI, confidence interval; RCT, randomized controlled trial; RR, risk ratio.

^a I² of 59% and *P*-value of 0.002 indicate heterogeneity of included studies.

^b Confidence interval includes both appreciable benefit and harm.